Altoida raises further $14 million to “democratize digital cognitive assessment at scale” via augmented reality (AR) and AI

Altoida snags Merck KGaA-led $14M funding round for Alzheimer’s diagnostic app (Fierce Biotech): The $14 million top-up came from a mix of old and new investors, co-led by Whitecap Venture Partners and Merck KGaA’s corporate VC arm, M Ventures, which also led the initial tranche of series A financing … The newly upsized funding will help Altoida add to its workforce, pay for intellectual property and regulatory filings and continue developing its tech platform to assess neurological function. Through an app downloaded to a patient’s own smartphone or tablet, Altoida’s tech first offers up a 10-minute test. A variety of Augmented Reality (AR)-powered exercises measure 11 areas of the brain that have been linked to Alzheimer’s. The video-game-like activities ask users to hide and relocate virtual objects around the room, simulate a fire evacuation and search for virtual items while a sound continuously plays. From there, Altoida’s AI analyzes the patient’s performance throughout the test. The resulting report highlights symptoms of cognitive decline—such as hand and gait errors, eye tracking, pupil dilation and more—and provides a score of the likelihood that they’ll develop Alzheimer’s within the next year. The Announcement: Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform (press release): Altoida, Inc., the precision neurology company pioneering non-invasive brain health measu...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Brain/ Mental Health Technology & Innovation Altoida assessment brain health cognitive decline digital cognitive assessment eye-tracking hand and gait errors M Ventures Merck neurocognitive neurocognitive assessment neurological Source Type: blogs